Statins and renal function.
Renal disease is often associated with an increased risk of vascular events. Moreover, an accelerated form of atherosclerosis commonly occurs in these patients. The reasons for these associations are not clearly defined but include the widespread presence of several established risk factors (eg, dyslipidemia, hypertension, and diabetes). Other predictors of atherosclerotic disease may also be abnormally elevated (eg, homocysteine, fibrinogen, and lipoprotein a). In addition, there is evidence that impaired renal function per se predicts vascular risk. Despite this high-risk background, the potential benefit of treatment with statins has not been widely investigated in these patients. The present review considers the evidence (experimental and clinical) that statins exert beneficial effects in patients with different types of renal disease. This includes improved renal function, decreased microalbuminuria, and a fall in blood pressure. Statins may also improve renal allograft survival. The potential mechanisms mediating these effects are considered. The interactions between statins and several risk factors that may be present in patients with impaired renal function are also considered. There is an urgent need to define the role of statins in these high-risk patients. Which is the statin of choice? This question is relevant because impaired renal function can interfere with statin pharmacokinetics. Furthermore, other drugs administered to these patients may cause serious interactions with statins.
D000328:Adult; D000419:Albuminuria / Q000517:prevention & control; D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000150:complications; D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000150:complications / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D004347:Drug Interactions; D006084:Graft Rejection; D006085:Graft Survival; D006538:Heptanoic Acids / Q000494:pharmacology / Q000627:therapeutic use; D006710:Homocysteine / Q000097:blood; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications* / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007668:Kidney / Q000187:drug effects*; D007674:Kidney Diseases / Q000150:complications* / Q000188:drug therapy; D007677:Kidney Function Tests; D016030:Kidney Transplantation; D015999:Multivariate Analysis; D016491:Peripheral Vascular Diseases / Q000188:drug therapy; D010919:Placebos; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012078:Renal Artery Obstruction / Q000150:complications; D012079:Renal Circulation; D006435:Renal Dialysis; D012307:Risk Factors; D019821:Simvastatin / Q000494:pharmacology / Q000627:therapeutic use; D013552:Swine; D016559:Tacrolimus / Q000494:pharmacology / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D000960:Hypolipidemic Agents; D007166:Immunosuppressive Agents; D010919:Placebos; D011758:Pyrroles; D006710:Homocysteine; D000069059:Atorvastatin; D019821:Simvastatin; D003404:Creatinine; D016559:Tacrolimus